Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study by Bhattarai, Shristi et al.
cancers
Brief Report
Prognostic Role of Androgen Receptor in Triple
Negative Breast Cancer: A Multi-Institutional Study
Shristi Bhattarai 1, Sergey Klimov 1, Karuna Mittal 1, Uma Krishnamurti 2,3, Xiaoxian (Bill) Li 2,3,
Gabriela Oprea-Ilies 4, Ceyda Sonmez Wetherilt 1, Ansa Riaz 1, Mohammed A. Aleskandarany 5 ,
Andrew R. Green 5 , Ian O. Ellis 3,5, Guilherme Cantuaria 6, Meenakshi Gupta 7,
Upender Manne 8, Johnson Agboola 3,9, Brett Baskovich 10, Emiel A. M. Janssen 3,11,
Grace Callagy 3,12, Elaine M. Walsh 12 , Anurag Mehta 3,13, Atika Dogra 13, Tanuja Shet 3,14,
Pooja Gajaria 14 , Tiffany Traina 15 , Haruna A. Nggada 3,16, Abidemi Omonisi 3,17,
Saad A. Ahmed 3,18 , Emad A. Rakha 3,5, Padmashree Rida 1,3,* and Ritu Aneja 1,3,*
1 Department of Biology, Georgia State University, Atlanta, GA 30303, USA
2 Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30322, USA
3 International Consortium for Advancing Research on Triple Negative Breast Cancer, Georgia State
University, Atlanta, GA 30303, USA
4 Department of Pathology, Emory University School of Medicine, Atlanta, GA 30322, USA
5 Nottingham Breast Cancer Research Centre, Division of Cancer and Stem Cells, School of Medicine,
University of Nottingham, Nottingham City Hospital, Nottingham NG5 1PB, UK
6 Department of Gynecologic Oncology, Northside Hospital Cancer Institute, Atlanta, GA 30342, USA
7 Department of Pathology, Piedmont Newnan Hospital, Newnan, GA 30265, USA
8 Department of Translational Anatomic Physiology, University of Alabama at Birmingham, Birmingham,
AL 3300, USA
9 Morbid Anatomy and Histopathology Department, Olabisi Onabanjo University, Ogun 112106, Nigeria
10 Department of Pathology, University of South Alabama College of Medicine, AL 36688, USA
11 Department of Pathology, Stavanger University Hospital, 4002 Stavanger, Norway
12 Discipline of Pathology, NUI Galway, Lambe Institute for Translational Research, Costello Road,
H91 TK33 Galway, Ireland
13 Research Department, Rajiv Gandhi Cancer Institute and Research Centre, Delhi 110-085, India
14 Department of Pathology, Tata Memorial Hospital, Mumbai 400 012, India
15 Department of Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 90710, USA
16 Department of Human Pathology, Faculty of Basic Clinical Sciences, College of Medical Sciences, University
of Maiduguri, Maiduguri, Borno state 1069, Nigeria
17 Department of Anatomic Pathology, Ekiti State University, Ado-Ekiti PMB 5363, Nigeria
18 Department of Pathology, Ahmadu Bello University, Zaria, Kaduna State 810241, Nigeria
* Correspondence: prida@gsu.edu or cgp_rida@yahoo.com (P.R.); raneja@gsu.edu (R.A.);
Tel.: +404-413-5417 (R.A.); Fax: +404-413-5301 (R.A.)
Received: 13 June 2019; Accepted: 11 July 2019; Published: 17 July 2019


Abstract: Background: The androgen receptor (AR) has emerged as a potential therapeutic target
for AR-positive triple-negative breast cancer (TNBC). However, conflicting reports regarding AR’s
prognostic role in TNBC are putting its usefulness in question. Some studies conclude that AR
positivity indicates a good prognosis in TNBC, whereas others suggest the opposite, and some
show that AR status has no significant bearing on the patients’ prognosis. Methods: We evaluated
the prognostic value of AR in resected primary tumors from TNBC patients from six international
cohorts {US (n = 420), UK (n = 239), Norway (n = 104), Ireland (n = 222), Nigeria (n = 180), and India
(n = 242); total n = 1407}. All TNBC samples were stained with the same anti-AR antibody using the
same immunohistochemistry protocol, and samples with ≥1% of AR-positive nuclei were deemed
AR-positive TNBCs. Results: AR status shows population-specific patterns of association with
patients’ overall survival after controlling for age, grade, population, and chemotherapy. We found
AR-positive status to be a marker of good prognosis in US and Nigerian cohorts, a marker of poor
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prognosis in Norway, Ireland and Indian cohorts, and neutral in UK cohort. Conclusion: AR status,
on its own, is not a reliable prognostic marker. More research to investigate molecular subtype
composition among the different cohorts is warranted.
Keywords: androgen receptor; triple-negative breast cancer; prognosis; multi-institutional study
1. Introduction
Triple-negative breast cancer (TNBC) is an aggressive subtype characterized by the lack of estrogen
(ER), progesterone (PR), and Her2 receptors. This designation masks the heterogeneity of this patient
population and the challenge of stratifying them for optimal treatment selection [1,2]. Due to the
paucity of treatment targets, cytotoxic chemotherapy is still the standard of care for TNBC, and there
is a need to develop new and more effective targeted treatments for these patients. Among several
therapeutic targets currently under study for the management of TNBC is the androgen receptor
(AR) [3–5]. The AR, a nuclear steroid hormone receptor, is expressed in 10–43% of TNBCs [6,7]. In the
absence of ERα, AR drives “luminal-like” gene expression patterns. One of the TNBC molecular
subtypes consistently identified via gene expression profiling is the Luminal Androgen Receptor
(LAR) subtype [3,4]. LAR TNBCs express full-length AR mRNA and AR target genes at high levels;
however, they tend to be less proliferative and generally respond poorly to chemotherapy in both the
neoadjuvant [8,9] and adjuvant settings [10]. Thus, AR expression reclassifies TNBCs into AR-positive
TNBCs and AR-negative TNBCs. Because LAR TNBCs are dependent on AR signaling for their growth,
AR-driven TNBC is considered an actionable subtype and targeting the AR pathway is an area of active
investigation [11,12].
Studies have explored the prognostic role of AR in TNBC to better understand androgen action in
TNBC, identify actionable factors that drive outcomes, and determine if testing for AR status should
become part of routine clinical practice for TNBCs. However, there are conflicting reports about AR’s
prognostic value in TNBC. While some studies report that AR-positivity is associated with better
prognosis [13,14], others either contend that an AR-positive phenotype portends worse long-term
outcomes [15,16] or that AR status has no significant impact on TNBC prognosis [17,18]. To some extent,
these discrepant results can be attributed to small sample sizes, differences in the ethnic composition
of cohorts, the anti-AR antibodies used for staining, staining/scoring method, and use of different
thresholds to define AR-positivity. Together these factors make comparisons of results across studies
and cohorts challenging. In this study, we evaluated the prognostic role of AR in 1,407 TNBC tumors
from seven ethnically and racially diverse populations. The tumor samples were processed identically,
and the differences in treatment protocols were accounted for.
2. Results and Discussion
AR expression varied widely in our cohorts (from 8.3% in the Nigerian TNBCs, to 55% in the UK
cohort). In the US cohort, 25% of all cases were AR-positive: Twenty percent among African Americans
(AA) and thirty percent among those of European decent (EA; p = 0.02; Figure 1). This finding is
consistent with previous reports [19]. The diversity in AR-positivity suggests our global cohorts could
differ substantially in their TNBC molecular subtypes.
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Figure 1. Androgen receptor (AR) expression in the seven cohorts of our multi-institutional study. 
(A) Representative micrographs showing AR expression in triple-negative breast cancer (TNBC) and 
their adjacent normal tissues, AR (brown) and nuclei (blue). Insets: 20× magnification. (B) Expression 
of AR in the different study cohorts. (C) Expression of AR among African Americans (AAs) and 
European Americans (EAs) in the US cohort. The p-value shows the significant difference in AR 
expression among AAs and EAs. 
Population-specific differences between cohorts became more apparent upon evaluating the 
prognostic value of AR among the cohorts in our study. We found that AR-positive TNBCs showed 
better OS than AR-negative TNBCs in the US (p = 0.03) and Nigerian (p = 0.01) cohorts among all 
patients (Figure 2A), as well as among adjuvant chemotherapy-treated patients (Figure 2B). By 
contrast, AR-positive TNBCs showed poorer prognosis (OS) than AR-negative TNBCs in the cohorts 
from Ireland (p = 0.08), Norway (p = 0.08), and India (p = 0.02) There was no statistically significant 
difference in OS between AR-positive TNBCs and AR-negative TNBCs in the UK (p = 0.79) cohort 
among all patients, or among adjuvant chemotherapy-treated patients (Figure 2A,B). 
Figure 1. Androgen receptor (AR) expression in the seven cohorts of our multi-institutional study.
(A) Representative icrographs showing AR expression in triple-negative breast cancer (TNBC) and
their adjacent normal tissues, AR (brown) and nuclei (blue). Insets: 20× magnification. (B) Expression
of AR in the different study cohorts. (C) Expression of AR among African Americans (AAs) and
European Americans (EAs) in the US cohort. The p-value shows the significant difference in AR
expression among AAs and EAs.
Population-specific differences between cohorts became more apparent upon evaluating the
prognostic value of AR among the cohorts in our study. We found that AR-positive TNBCs showed
better OS than AR-negative TNBCs in the US (p = 0.03) and Nigerian (p = 0.01) cohorts among all
patients (Figure 2A), as well as among adjuvant chemotherapy-treated patients (Figure 2B). By contrast,
AR-positive TNBCs showed poorer prognosis (OS) than AR-negative TNBCs in the cohorts from
Ireland (p = 0.08), Norway (p = 0.08), and India (p = 0.02) There was no statistically significant difference
in OS between AR-positive TNBCs and AR-negative TNBCs in the UK (p = 0.79) cohort among all
patients, or among adjuvant chemotherapy-treated patients (Figure 2A,B).
These survival trends did not change appreciably when the cut-point for AR-positivity was changed
from 1% to 10%, or when an optimal cut-point was used to see if changing the cut-point affected
the prognostic trend (Table S1). Multivariable Cox regression analyses that adjusted for potentially
confounding variables, such as age, grade, chemotherapy, and population revealed two main trends.
(1) In the US and Nigerian cohorts (wherein AR-positive TNBCs have a better prognosis compared
with AR-negative TNBCs), the only variables significantly and independently associated with OS were
being AA, being native African, and AR positive/negative status. (2) In the cohorts from Norway,
Ireland, and India (wherein AR-positive TNBCs have a poorer prognosis compared with AR-negative
TNBCs), age, being from India, and AR positive/negative status were all significantly and independently
associated with OS. Thus, in five TNBC cohorts from four continents, AR positive/negative status shows
population-specific patterns of association with OS (Table 1). One cohort showed no pattern of association
with OS.
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Figure 2. Prognostic significance of the androgen receptor (AR) in different study cohorts. (A) Kaplan 
Meier survival curves for AR-negative TNBC (blue) and AR-positive TNBC (red) patients from (i) UK 
overall cohort, (ii) US overall cohort, (iii) Nigeria overall cohort, (iv) Norway overall cohort, (v) 
Ireland overall cohort, and (vi) India overall cohort. (B) Kaplan Meier survival curves for adjuvant-
chemotherapy-treated AR-negative TNBC (blue) and AR-positive TNBC (red) patients from (i) UK 
cohort, (ii) US cohort, (iii) Nigeria cohort, (iv) Norway cohort, (v) Ireland cohort, and (vi) India cohort. 
These survival trends did not change appreciably when the cut-point for AR-positivity was 
changed from 1% to 10%, or when an optimal cut-point was used to see if changing the cut-point 
affected the prognostic trend (Table S1). Multivariable Cox regression analyses that adjusted for 
potentially confounding variables, such as age, grade, chemotherapy, and population revealed two 
main trends. (1) In the US and Nigerian cohorts (wherein AR-positive TNBCs have a better prognosis 
Figure 2. Prognostic significance of the androgen receptor (AR) in different study cohorts. (A) Kaplan
Meier survival curves for AR-negative TNBC (blue) and AR-positive TNBC (red) patients from (i)
UK overall cohort, (ii) US overall cohort, (iii) Nigeria overall cohort, (iv) Norway overall cohort,
(v) Ireland overall cohort, and (vi) India overall cohort. (B) Kaplan Meier survival curves for
adjuvant-chemotherapy-treated AR-negative TNBC (blue) and AR-positive TNBC (red) patients from
(i) UK cohort, (ii) US cohort, (iii) Nigeria cohort, (iv) Norway cohort, (v) Ireland cohort, and (vi)
India cohort.
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Table 1. Multivariate analysis to reveal population-specific differences between cohorts. AA = African
American; AR = androgen receptor. Bold refers to significant p-values.
Multivariate Cox Regression Analysis of Common Clinicopathological Variables and AR
Variables US and Nigeria Study Cohorts Norway, Ireland and India StudyCohorts
Hazard Ratio (95% CI) p-value Hazard Ratio (95% CI) p-value
Overall Survival
Age <50 vs. ≥50 1.00 (0.99–1.01) 0.3934 1.03 (1.01–1.05) <0.001
Grade 2 0.77 (0.86–8.84) 0.085 0.25 (0.05–1.17) 0.0801
Grade 3 3.63 (1.15–11.44) 0.0275 0.37 (0.09–1.56) 0.1777
Adjuvant
Chemotherapy
treated vs.
non-treated 0.72 (0.39–1.32) 0.2877 0.91 (0.56–1.47) 0.7026
Population AA 1.82 (1.30–2.53) 0.0004 - -
Population African 11.22 (8.11–15.51) <0.0001 - -
Population Indian - - 0.49 (0.27–0.89) 0.0201
Population Irish - - 0.79 (0.48–1.28) 0.3462
AR AR-positive vs.AR-negative 1.70 (1.10–2.61) 0.0157 0.58 (0.37–0.90) 0.0154
Some noteworthy limitations of our study include potential cohort-to-cohort differences in tissue
fixation and the lack of centralized AR staining for some of the cohorts. Notwithstanding these caveats,
we believe that by rigorously addressing previously reported inconsistent results regarding AR’s
prognostic role in TNBC, our multi-institutional study has allowed the TNBC field to move forward.
We have demonstrated that AR’s prognostic value likely hinges on the proportions of the
TNBC molecular subtypes (especially non-LAR subtypes) present in the cohorts, and perhaps other
covert modifiers of AR biology. Candidate modifiers in different populations might include patients’
biogeographic ancestry, AR splice variants, epigenetic factors, tumor microenvironment, and repeat
length polymorphisms (RLPs) in the AR gene. For example, among the alternatively spliced transcripts
known to be generated from the AR gene, the constitutively active variant AR-V7 is often expressed in
TNBC cells along with the full-length mRNA, but it regulates a transcriptional program distinct from
full-length AR, and may affect outcomes. At present, little is known about the expression of AR-V7
and other splice variants in TNBC tumors in different populations. Few studies have examined the
RLPs or tumor microenvironment in AR positive/negative TNBC tumors and correlated these features
with the tumors’ molecular subtypes. Moreover, amplification of and mutations in the AR gene have
been shown to drive castration- resistant prostate cancer; thus, further analysis of the mutational status
of the AR gene and its downstream signaling components would shed some light on the biology of
AR in different TNBCs arising in different populations. The aforementioned under-studied potential
modifiers of AR biology could affect not only patients’ prognosis following chemotherapy, but also
responses to AR-targeting agents, and are, therefore, very clinically relevant.
Another potential confounder of our results may be the molecular apocrine (MA) nature of the
TNBCs in our cohorts. Studies have shown that AR binds ER-binding cis-regulatory elements in
MA tumors and drives expression of genes normally regulated by ER. More importantly, a study of
58 transcriptionally defined MA tumors found that a significant proportion of these tumors showed
expression of AR mRNA via qRT-PCR even though they were AR-negative via IHC [20]. These
intriguing findings raise the possibility that some of the TNBC tumors in our cohorts (as well as in
cohorts used in previous studies) that were classified as AR-negative based on IHC, may, in fact,
be MA tumors that express detectable levels of AR mRNA and show activation of AR-target genes.
In other words, IHC-based detection of AR expression may not be sensitive enough to identify all
TNBC tumors in which AR-mediated signaling is active, nor to identify patients likely to respond to
the AR-targeted treatments. Moreover, studies have shown AR as an independent predictor for the
complete pathological response in breast cancer [21]. Since all our study cohorts are comprised of the
adjuvant chemotherapy-treated patients and patients who did not receive any systemic therapy, it will
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be worth exploring the prognostic and predictive role of AR in similarly diverse cohorts in the context
of neoadjuvant treatment.
3. Materials and Methods
3.1. Study Cohorts and Samples
All aspects of this study were approved by Institutional Review Boards of the institutions involved
(IRB number: H19306). Materials and data were shared in accordance with the stipulations of Material
Transfer Agreements and Data User Agreements between Georgia State University (GSU) and the other
participating institutions as listed in Table S2). A total of 1407 cases consecutively diagnosed with
TNBC were identified from the electronic health records of multiple institutions (Table S2). Samples
were collected from institutions in the US (n = 420), UK (n = 239), Norway (n = 104), Ireland (n = 222),
Nigeria (n = 180), and India (n = 242). Resection samples from primary tumors were formalin-fixed
and paraffin-embedded (FFPE). Samples from Nigeria, US, and Norway were processed at GSU, and
the samples from the UK, India and Ireland were processed at their respective institutions.
Clinicopathological data (Table 2; reviewed and provided by a pathologist from the respective
hospitals), race information (for US cohort only), overall survival (OS), and deidentified tissue blocks
were available for all cases. All patients in the Nigerian cohort received adjuvant chemotherapy; by
contrast, the remaining cohorts included a mix of patients who did not receive any systemic treatment
in the adjuvant setting and patients who received adjuvant chemotherapy. Patient consent was not
required, because all samples were archival.
Table 2. Patient demographic and tumor data stratified by cohort; n (%).
Clinicopathological Variables of Study Cohorts
Variables UK Norway Ireland US Nigeria India
n = 239 n = 104 n = 222 n = 420 n = 180 n = 242
Age
<50 128 (53.55) 45 (43.3) 55 (24.8) 129 (30.7) 97 (53.9) 122 (50.4)
≥50 111 (46.45) 59 (56.7) 167 (75.2) 291 (69.3) 83 (46.1) 120 (49.6)
Clinical stage
I/II 212 (88.7) 91 (87.5) 177 (79.7) 320 (76.2) NA NA
III/IV 26 (10.9) 11 (10.6) 34 (15.3) 84 (20) NA NA
Missing 1 (0.4) 2 (1.9) 11 (5.0) 16 (3.8) NA NA
Grade
1 5 (2.1) 1 (1.0) 2 (0.9) 11 (2.6) 7 (3.9) 0 (0)
2 12 (5.0) 15 (14.4) 31 (14) 79 (18.8) 68 (37.8) 13 (5.4)
3 221 (92.5) 83 (79.8) 189 (85.1) 322 (76.7) 101 (56.1) 228 (94.2)
Missing 1 (0.4) 5 (4.8) 0 (0) 8 (1.9) 4 (2.2) 1 (0.4)
Chemotherapy
Treated 106 (44.4) 81 (77.9) 164 (73.9) 305 (72.6) 180 (100) 163 (67.4)
Untreated 110 (46) 20 (19.2) 58 (26.1) 56 (13.3) 0 (0) 46 (19.2)
Missing 23 (9.6) 3 (2.9) 0 (0) 59 (14.1) 0 (0) 33 (13.4)
Vital status
Dead 112 (46.9) 44 (42.3) 56 (25.2) 131 (31.2) 139 (77.2) 28 (11.6)
Alive 127 (53.1) 60 (57.7) 166 (74.8) 289 (68.8) 41 (22.8) 214 (88.4)
Androgen
Receptor
Positive 130 (54.9) 34 (32.7) 55 (24.77) 104 (24.8) 15 (8.3) 55 (22.7)
Negative 109 (45.1) 70 (67.3) 167 (75.3) 316 (75.2) 165 (91.7) 187 (77.3)
3.2. Immunohistochemistry (IHC)
All samples in the six cohorts were stained using the following protocol: Briefly, the FFPE TNBC
primary tumor resection samples were deparaffinized following by rehydration in a series of ethanol
baths (100%, 90%, 75%, and 50%). Heat-induced retrieval of antigen epitopes was performed in citrate
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buffer (pH 6.0) using pressure cooker at 15 psi for 30 min. Next, the samples were quenched using
hydrogen peroxide for 20 min, followed by blocking with the Ultra-Vision protein block (Life Sciences,
Fremont, CA, USA) for 10 min. Samples were then incubated for 60 min at room temperature with
anti-AR primary antibody (Monoclonal Mouse Anti-Human Androgen Receptor, clone AR 441, DAKO)
at 1:50 dilution. Next, the samples were incubated with MACH2 HRP-conjugated secondary antibody
(BioCare Medical, Pacheco, CA, USA) for 30 min. The AR antigen was visualized using the Betazoid 3,
3-diaminobenzidine Chromogen Kit (BioCare Medical). The tissue sections were counter stained with
Mayer’s hematoxylin for 1 min. Slides were then dehydrated in alcohol, cleared in xylene, and mounted
with mounting medium. Appropriate negative and positive controls were used during staining.
3.3. Assessment of IHC Staining
Nuclear AR staining is indicative of active receptors, because AR can translocate to the nucleus
upon ligand binding. Therefore, the stained slides were scored for the percentage of tumor-cell nuclei
that showed AR-positivity. TNBC samples were considered AR-negative if they had <1% of the tumor
nuclei positive for AR; samples that had AR in ≥1% of the nuclei were considered AR-positive. Samples
from the Nigerian, US, and Norwegian cohorts were stained and scored centrally (at GSU) and the
samples in the UK, Indian, and Irish, cohorts were stained and scored at the respective institutions by
two independent pathologists without prior knowledge of the patients’ pathologic or outcome data.
For cross validation of the IHC scores, stained slides of grade- and stage-matched cases (representing
20–30% of each cohort) were selected from each cohort (along with the positive and negative control
slides from each round of staining). The slides were reviewed and re-scored at Nottingham University
Hospital by two pathologists who were blinded to the clinical annotation and previous IHC scores.
The scores from the second round of scoring showed >99% concordance with the original IHC scores.
3.4. Statistical Analyses
Bar graphs were plotted using Excel and SPSS. Experimental groups were compared using
Student’s t-test, and p-values were calculated with p < 0.05 considered statistically significant.
Statistical analyses were carried out with SAS 9.4® software (Cary, NC, USA). Differences between
clinicopathological proportions were determined using the χ2 test. Differences between baseline
IHC biomarker expressions or continuous clinicopathological variables were evaluated via a 2-tailed
t-test. Univariate Kaplan-Meier curves were used to investigate the effect of AR status (positive vs.
negative) on OS, and the log-rank test was used to assess the statistical significance of between-group
survival differences. Multivariable Cox Proportional Hazard models were used to adjust for grade,
chemotherapy, population, and age with significance being determined with the Wald chi-square
test. For all clinical survival analysis, we used the OS, which was calculated as the time interval from
surgery until death, and death was used as an event.
4. Conclusions
Our findings, therefore, provide a strong impetus to pursue future studies that integrate
transcriptomic and genomic information to better parse and refine the classification of TNBCs.
Deeper dissection of the pathways upstream/downstream of AR, as well as transcriptomic, genomic,
and epigenetic profiling of samples from different patient populations, could move us from the currently
used coarse categories towards finer signatures. Signatures that may reclassify AR positive/negative
TNBCs into more clinically actionable subgroups.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/7/995/s1,
Table S1: Table showing overall survival of AR positive TNBC at different thresholds of AR, Table S2: Table
representing number of cases and sample type evaluated for AR expression in global TNBC cohort and diverse
institutions from US.
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